Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 30;51(1):1103.
doi: 10.1007/s11033-024-10034-5.

PARP inhibitors in prostate cancer: clinical applications

Hamidreza Saeidi  1 , Mohsen Sarafbidabad  2
Affiliations
Review

PARP inhibitors in prostate cancer: clinical applications

Hamidreza Saeidi et al. Mol Biol Rep. .

Abstract

Despite recent advancements in the treatment of metastatic castrate-resistant prostate cancer (mCRPC), this disease remains lethal. A novel family of targeted pharmaceuticals known as poly-ADP-ribose polymerase (PARP) inhibitors has been developed to treat mCRPC patients with homologous recombination repair (HRR) gene alterations. The FDA recently approved olaparib and rucaparib for treating mCRPC patients with HRR gene alterations. Ongoing trials are investigating combination therapies involving PARP inhibitors combined with radiation, chemotherapy, immunotherapy, and androgen receptor signaling inhibitors (ARSIs) to improve the effectiveness of PARP inhibitors and broaden the range of patients who can benefit from the treatment. This review provides an overview of the development of PARP inhibitors in prostate cancer and analyzes the mechanisms underlying their resistance.

Keywords: Homologous recombination repair; PARP inhibition; Prostate cancer; Targeted therapy.

PubMed Disclaimer

References

    1. Siegel RL, Giaquinto AN, Jemal A, Cancer statistics (2024) CA Cancer J Clin. 2024; 74(1): 12–49. https://doi.org/10.3322/caac.21820 . Epub 2024 Jan 17. PMID: 38230766
    1. Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L et al (2023) Castration-resistant prostate Cancer: from uncovered resistance mechanisms to current treatments. Cancers (Basel) 15(20):5047. https://doi.org/10.3390/cancers15205047 . PMID: 37894414; PMCID: PMC10605314 - DOI
    1. Wang Y, Zheng K, Huang Y, Xiong H, Su J, Chen R et al (2021) PARP inhibitors in gastric cancer: beacon of hope. J Exp Clin Cancer Res 40(1):211. https://doi.org/10.1186/s13046-021-02005-6 . PMID: 34167572; PMCID: PMC8228511 - DOI
    1. Li J, Li Q, Zhang L, Zhang S, Dai Y (2023) Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function. Biomed Pharmacother 157:114028. https://doi.org/10.1016/j.biopha.2022.114028 . Epub 2022 Nov 18. PMID: 36410122 - DOI
    1. Kanev PB, Atemin A, Stoynov S, Aleksandrov R (2024) PARP1 roles in DNA repair and DNA replication: the basi(c)s of PARP inhibitor efficacy and resistance. Semin Oncol 51(1–2):2–18. https://doi.org/10.1053/j.seminoncol.2023.08.001 . Epub 2023 Sep 6. PMID: 37714792 - DOI

MeSH terms

LinkOut - more resources